1. Home
  2. GIPR vs AZTR Comparison

GIPR vs AZTR Comparison

Compare GIPR & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Income Properties Inc.

GIPR

Generation Income Properties Inc.

HOLD

Current Price

$0.25

Market Cap

2.0M

Sector

Real Estate

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.24

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIPR
AZTR
Founded
2015
2014
Country
United States
United States
Employees
4
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
GIPR
AZTR
Price
$0.25
$0.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
102.5K
20.8M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.12
N/A
Revenue Next Year
$0.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.10
52 Week High
$1.99
$1.40

Technical Indicators

Market Signals
Indicator
GIPR
AZTR
Relative Strength Index (RSI) 22.11 55.86
Support Level N/A $0.14
Resistance Level $0.87 $0.25
Average True Range (ATR) 0.03 0.04
MACD -0.00 0.01
Stochastic Oscillator 0.40 49.48

Price Performance

Historical Comparison
GIPR
AZTR

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: